NCT05803772View on ClinicalTrials.gov

A Study to Evaluate Efficacy and Safety of Distal Jejunal-release Dextrose Beads Formulation in Subjects With a Pathological Oral Glucose Tolerance Test

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

March 31, 2023

Primary Completion Date

February 12, 2024

Study Completion Date

February 12, 2024

Conditions
PreDiabetesGlucose Tolerance Impaired
Interventions
DRUG

APHD-012

Drug: APHD-012 Distal jejunal-release dextrose beads (Aphaia technology, AT)

DRUG

APH-012P

Distal jejunal-release placebo beads

Trial Locations (3)

93405

Cell-B s.r.o., Levice

Unknown

ALIAN, s.r.o., Bardejov

MEDISPEKTRUM s.r.o., Bratislava

Sponsors
All Listed Sponsors
lead

Aphaia Pharma US LLC

INDUSTRY

NCT05803772 - A Study to Evaluate Efficacy and Safety of Distal Jejunal-release Dextrose Beads Formulation in Subjects With a Pathological Oral Glucose Tolerance Test | Biotech Hunter | Biotech Hunter